Mineralys Therapeutics
A fully remote Pennsylvania drug developer with one blood pressure pill, lorundrostat, an FDA decision due December 22, and a sales force being hired before a rival got there first.
Q2 2026 results release, Aug 11, 2026- Revenue
- $0 no sales of any kind yet; lorundrostat is still under FDA review.
- Cash
- $661.4M cash and investments at June 30, 2026, said to last into 2028.
- Debt
- $100M drawn from a loan of up to $500M at about 9.9%, due 2031.
- Watch
- Dec 22 FDA target date to decide on lorundrostat for hypertension.
- AI
- Not claimed its FY2025 10-K never mentions artificial intelligence.
- Hiring
- 40 of 40 open postings tagged US Remote; 30 are field sales or medical roles tied to a region.
- Listings
- 28 → 34 remote listings since Oct 10.
Every dollar so far came from investors and lenders.
Mineralys has never sold anything. It spends on trials and now on a launch team, paid for by share sales ($578M in 2025 alone) and a new loan. Income starts only if the FDA approves lorundrostat, its single drug.
10-Q Q2 2026 (filed Aug 11, 2026); 10-K FY2025 cash flow- 1Two pivotal trials already in the FDA fileLaunch-HTN (1,083 people) cut systolic pressure 9.1 mmHg more than placebo at week 6; Advance-HTN (285 people) met its 24-hour goal.10-K FY2025 (filed Mar 12, 2026)
- 2It now owns the drug outrightTanabe assigned the lorundrostat patents to Mineralys on Oct 27, 2026, and royalties on sales were cancelled in June. Milestones of up to $255M remain.8-K, Tanabe termination agreement (filed Oct 29, 2026)
- 3Patent cover into the 2040s16 patent families, with nominal expiry from 2035 to about 2046, before any extensions.10-K FY2025 (filed Mar 12, 2026)
Still losing money: $171 million in FY2025.
Plenty of cash for a launch, but the loan has teeth: it can come due in June 2028 if lorundrostat is not approved by Sept 30, 2027, and from 2028 it requires minimum yearly sales.
The rest of Mineralys Therapeutics, for members.
The fine print, who gets paid most, where it looks headed and our calls. Free for 3 days, then $9 a month.
- 03
What the filings say, and what we think it means.
9 flags, each with our read
- 04
Sales is paid 6% over market.
Posted pay against the market, 1 team
- 05 · 06
How Mineralys Therapeutics uses AI, and what its hiring says.
- 07
Your view of the next year, in a share price.
- 08
The signals, and which way they push.
5 signals
- 09
Where Mineralys Therapeutics ends up, if we had to bet.
5 predictions, with odds
Read by the Still Remote research agent on November 3, 2026 from the sources linked on this page. Facts and scenarios only, not investment advice.